Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).

Abstract

Treatment of superficial bladder carcinoma in situ with Connaught BCG (ImmuCyst) significantly increased complete response rate and extended the disease-free interval when compared with Doxorubicin (DOX) chemotherapy. In 54 patients treated with ImmuCyst, 74% showed complete response compared with 42% of 60 patients treated with DOX. The median disease-free time was 48.2 months for BCG and 5.9 months for DOX treatment. Types and severity of adverse reactions were similar for both treatments and within tolerable ranges.

• Authors: L Barreto, Z Csizer, J D Sparkes
• Journal: Developments in biological standardization (Dev Biol Stand) Vol. 77 Pg. 229-31 ( 1992) ISSN: 0301-5149 [Print] Switzerland
• PMID: 1426667 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• BCG Vaccine
• Vaccines, Attenuated
• Doxorubicin

Topics

• Administration, Intravesical
• Aged
• BCG Vaccine (administration & dosage, adverse effects, therapeutic use)
• Carcinoma in Situ (drug therapy, therapy)
• Carcinoma, Transitional Cell (drug therapy, mortality, therapy)
• Doxorubicin (administration & dosage, adverse effects, therapeutic use)
• Fever (etiology)
• Follow-Up Studies
• Humans
• Middle Aged
• Neoplasm Recurrence, Local (prevention & control)
• Neoplasms, Multiple Primary (mortality)
• Survival Analysis
• Urinary Bladder Neoplasms (drug therapy, mortality, therapy)
• Urologic Diseases (etiology)
• Vaccines, Attenuated (administration & dosage, adverse effects, therapeutic use)